LTR Pharma Limited (AU:LTP) has released an update.
LTR Pharma Limited, the company dedicated to improving men’s health with its innovative SPONTAN® Nasal Spray for Erectile Dysfunction, has requested an immediate trading halt on the ASX pending an announcement. The halt is in anticipation of the initial clinical trial results for SPONTAN® and is expected to lift by Thursday, 6 June 2024, or when the results are disclosed, whichever comes first. This move underscores the company’s commitment to addressing men’s health issues with novel treatments that promise fast-acting relief.
For further insights into AU:LTP stock, check out TipRanks’ Stock Analysis page.
